Efficacy of paracetamol for the treatment of patent ductus arteriosus in preterm neonates

Gianluca Terrin1*, Francesca Conte2, Antonella Scipione2, Erica Bacchio2, Maria Giulia Conti2, Rosalia Ferro2, Flavia Ventriglia2 and Mario De Curtis2

Abstract
Inhibitors of the cyclo-oxygenase component of prostaglandin-H2 synthetase, namely indomethacin and ibuprofen, are commonly used in the treatment of hemodynamically significant patent ductus arteriosus. These drugs are associated with serious adverse events, including gastrointestinal perforation, renal failure and bleeding. The role of paracetamol, an inhibitor of the peroxidase component of prostaglandin-H2 synthetase, has been proposed for the treatment of patent ductus arteriosus. We report a series of 8 neonates (birth weight: 724 ± 173 g; gestational age: 26 ± 2 weeks) treated with paracetamol for a hemodynamically significant patent ductus arteriosus, because of contraindications to ibuprofen or indomethacin. Successful closure was achieved in 6 out of 8 babies (75%). Median ductal diameter was significantly reduced after treatment (from 1.2 mm, range 1.0-2.5 mm to 0.6 mm, range 0.0-2.5 mm, p = 0.038). No adverse or side effects were observed during treatment. On the basis of these results, paracetamol could be considered a promising and safe therapy for the treatment of patent ductus arteriosus in neonates.

Keywords: Patent ductus arteriosus, Paracetamol, COX-inhibitors, Ibuprofen, Indomethacin

Background
A persistently patent ductus arteriosus (PDA) has significant clinical consequences in preterm neonates during the recovery period from respiratory distress syndrome [1]. Ductal patency is regulated by the circulating prostaglandins (PGs) produced by an enzyme system, namely prostaglandin-H2 synthetase (PGHS), which is composed of two active sites: cyclo-oxygenase (COX) and peroxidase [2,3]. Indomethacin and ibuprofen are COX-inhibitor drugs commonly used for the treatment of hemodynamically significant (hs)-PDA. Despite the about 70% success rate, COX-inhibitors are frequently contraindicated in early life and their use has been associated with serious adverse events, such as gastrointestinal perforation, renal failure and bleeding [4-11]. Paracetamol, an inhibitor of the peroxidase component of PGHS, is commonly used in pediatric age, and has been recently proposed for the treatment of PDA [12-22]. We aimed to evaluate the efficacy of paracetamol in the early treatment of PDA in preterm neonates presenting contraindication to COX-inhibitors.

Case presentation
We report a case series of neonates with hs-PDA treated with paracetamol because of contraindication to ibuprofen or indomethacin, who were observed at the Neonatal Intensive Care Unit of the University of Rome “Sapienza”, from January 2012 to October 2013. During this study period, based on our policy, neonates with gestational age (GA) at birth < 32 weeks were evaluated daily to detect the presence of hs-PDA. Neonates with hs-PDA were treated with paracetamol in the presence of contraindications to ibuprofen or indomethacin (i.e. urine output < 1 ml/kg/h, intraventricular hemorrhage, platelet count < 60,000/mm3, hyperbilirubinemia requiring exchange transfusion, signs of feeding intolerance or gastrointestinal bleeding). The condition of hs-PDA was defined by the presence of at least one of the following criteria: internal ductal diameter ≥ 1.5 mm, left-atrium-to-aortic-root ratio > 1.6, unrestrictive pulsatile transdudal flow, reverse or absent diastolic flow in the descending aorta [23]. Paracetamol was given at doses ranging from 7.5 to 15 mg/kg every 4–6 hours, with a maximum daily dose of 120 mg/kg.
dose of 60 mg/Kg. We collected, in a specific reporting form, data regarding GA, sex, mode of delivery, birth weight (BW), Apgar score at 5 minutes, weight at enrollment, age at enrollment, contraindication to COX-inhibitor use and echocardiographic characteristics of PDA before and after therapy, obtained from the clinical charts and nursing records. Efficacy was defined by the rate of patients in whom we observed ductal closure (defined by the absence of shunt or diameter < 0.5 mm without any other hemodynamic implications) at echocardiographic examination performed daily during the study period. To monitor safety of paracetamol treatment, we collected data regarding serum concentration of liver enzymes, total and direct bilirubin, creatinine and urea nitrogen. Occurrence of common morbidities of prematurity (i.e. bronchopulmonary dysplasia, intraventricular hemorrhage, necrotizing enteroocolitis), fatal events and side effects were also collected. The study was approved by the ethics committee of University of Rome La Sapienza. The χ² test and Fisher’s exact test were used for categorical variables. The level of significance for all statistical tests was 2-sided, p < 0.05. Statistical analysis was performed with SPSS Version 16.0 for Windows (SPSS Inc., Chicago, IL).

During the study period we observed 8 neonates treated with paracetamol for an hs-PDA. Successful closure was obtained in 6 out of 8 neonates. Median ductal diameter was significantly reduced after treatment (from 1.2 mm, range 1.0-2.5 mm to 0.6 mm, range 0.0-2.5 mm, p = 0.038). Baseline clinical findings, contraindications to COX-inhibitors and echocardiographic characteristics of our study population are reported in Table 1.

The two patients in whom paracetamol failed to close the ductus, intravenous ibuprofen (at a dose of 10 mg/kg followed by 5 mg/kg after 24 and 48 hours) was given considering that previous contraindications were no longer present. Surgical ligation was finally needed for both patients after ibuprofen failure. None of our patients experienced re-opening of the ductus after closure. No adverse or side effects were observed during treatment (Table 2). One of the 2 patients who failed treatment with paracetamol developed bronchopulmonary dysplasia.

**Conclusions**

Our case series demonstrates the efficacy of paracetamol in hs-PDA in preterm neonates with contraindication to COX inhibitors. Nine case series involving a total number of 67 neonates treated with paracetamol for PDA, have been previously reported [12-20]. The larger series evaluating efficacy of paracetamol in a similar setting, included a maximum number of 10 patients [13,16,20]. Six studies verified the efficacy of paracetamol in very low birth weight neonates [12,13,16,17,19,20]; four of them reported a rate of ductal closure of 71-100% [12,13,16,17], while 2 series observed a very low efficacy rate (i.e. 0-20%) [19,20]. In particular, Alan S. et al. reported the failure of paracetamol in 3 neonates treated with this drug after one or more unsuccessful courses of ibuprofen [19]. In the case series reported by Rooftooff et al., paracetamol was ineffective in 8 out of 10 neonates [20]; however, these patients had a lower GA and BW [20] and started paracetamol treatment later [19,20] than the patients in our case series. All these data suggest that lower GA and BW associated with previous courses of ibuprofen or later ductal treatment may negatively influence the response to paracetamol.

### Table 1 Main demographic, clinical and echocardiographic findings of preterm neonates before treatment with paracetamol

| Characteristics at baseline | N | 8 |
|----------------------------|---|---|
| Body weight at birth, g    |   | 724 ± 173 |
| Gestational age at birth, weeks | | 26 ± 2 |
| Caesarian section, n (%)   |   | 6 (75.0) |
| Male, n (%)                |   | 6 (75.0) |
| Apgar at 5 minutes         |   | 5 ± 1 |
| Resuscitation at birth, n (%) | | 8 (100) |
| Body weight at enrollment, g | | 743.7 ± 167.6 |
| Age at enrollment, h       |   | 66 ± 28 |

| Contraindication to COX-inhibitors | N | 4 (50.0) |
|------------------------------------|---|---------|
| Oliguria, n (%)                    |   |         |
| Thrombocytopenia, n (%)            | 2 (25.0) |
| Intraventricular hemorrhage, n (%) | 1 (12.5) |
| Blood in gastric aspirates, n (%)  | 1 (12.5) |
| Hyperbilirubinemia requiring phototherapy, n (%) | 4 (50.0) |
| Hyperbilirubinemia requiring exchange transfusion, n (%) | 0 (0.0) |

| Echocardiographic findings | Diameter of the ductus ≥ 1.5 mm, n (%) | 3 (37.5) |
|---------------------------|-------------------------------------------|---------|
|                           | Left-atrium-to-aortic-root ratio >1.6, n (%) | 6 (75.0) |
|                           | Unrestrictive pulsatile transductal flow, n (%) | 1 (12.5) |
|                           | Reverse flow in the descending aorta, n (%) | 2 (25.0) |

Notes. Data are expressed as mean ± standard deviation, when not specified.

### Table 2 Serum level of liver enzymes and bilirubin before and after treatment with paracetamol

|                       | At baseline | At end of therapy | p    |
|-----------------------|-------------|-------------------|------|
| Alanine aminotransferase, U/L | 56 (8-78)  | 55 (4-78)        | 0.878|
| Aspartate aminotransferase, U/L | 54 (26-80) | 31 (8-62)        | 0.015|
| Bilirubinemia, mg/dl    | 7.6 (3.4-12.8) | 5.0 (2.7-7.5)   | 0.050|

Notes. Data are expressed as median (range: upper - lower values).
[24-26]. Accordingly, we observed a failure of paracetamol treatment in 2 subjects with very low GA. On the other hand, the high rate of ductal closure observed in our population could be associated with the earlier start of paracetamol treatment compared with the vast majority of the previous reports.

In five previous studies, paracetamol was administered by enteral route [12,14-16,18] and in 4 by intravenous route [13,17,19,20]. All of our patients were given paracetamol intravenously because they presented signs of feeding intolerance (i.e., gastric residuals, vomiting, abdominal distension). Even if parenteral route is associated with higher peak and less variability of plasma concentration [27], apparently a similar rate of ductal closure was observed also in reports using oral paracetamol. High doses (60 mg/kg/day) of paracetamol were used in 7 out of 9 previous studies [12-15,18-20], while 2 studies reported the administration of lower doses of paracetamol (30–45 mg/kg/day), apparently without any reduction in efficacy [16,17]. However no study comparing different dosing regimens is available at the moment.

The mechanism of action of paracetamol remains largely uninvestigated. Paracetamol, by inhibiting PG production [3], firstly induces smooth muscle constriction and narrowing of the lumen, similarly to COX-inhibitors. In the subsequent phases of ductal closure, platelet aggregation plays a crucial role in the formation of a thrombus that occludes ductal lumen [28,29]. A lower anti-platelet activity of paracetamol compared to that of COX-inhibitors may positively influence this phase of the closure process [3]. In any case, future studies should be performed to shed light on the mode of action of paracetamol.

Although interesting, the results of our study suffer from some limitations. Similarly to previous case series, ours is based on a limited number of neonates. Recently, two randomized clinical trials have demonstrated similar efficacy of oral paracetamol compared with oral ibuprofen [21,22]. Although interesting, results of these trials do not clarify many aspects related to paracetamol use in neonatal age (i.e., optimal dosage, time to start therapy and route of administration). In addition these trials present significant limitations such as inadequate sample power calculation and absence of per intention-to-treat analysis. Pharmacokinetic studies were not performed in our population to avoid adjunctive procedures and blood collections in preterm infants at high risk of iatrogenic anemia [30,31]. Nevertheless previous studies have demonstrated that the doses used in our study are safe and associated with optimal levels of serum paracetamol concentrations [13].

Our results encourage further well designed studies aimed at verifying the efficacy of paracetamol also as first choice agent in the treatment of PDA.

Consent
Written informed consent was obtained from the parents of the patients for the publication of this report.

Abbreviations
BW: Birth weight; COX: Cyclo-oxygenase; GA: Gestational age; HS-PDA: Hemodynamically significant patent ductus arteriosus; PDA: Patent ductus arteriosus; PGHS: Prostaglandin-H2 synthetase; PGs: Prostaglandins.

Competing interests
All authors declare that they have no potential, perceived, or real conflict of interest to disclose. No honorarium, grant, or other form of payment was given to anyone to produce this manuscript.

Authors’ contributions
GT, MDC and FV designed the study; GT and FC performed data monitoring and statistical analysis; AS, EB, MGC, RF and CN cared for the patients, collected data and wrote the first draft of the manuscript; FV performed echocardiographic evaluations and all the authors revised and approved the final version of the paper.

Author details
1Department of Gynecology-Obstetrics and Perinatal Medicine, University “La Sapienza”, Viale del Policlinico 155, 00161 Rome, Italy. 2Department of Pediatrics, University “La Sapienza”, Rome, Italy.

Received: 6 December 2013 Accepted: 16 February 2014
Published: 20 February 2014

References
1. Hamrick SE, Hansmann G: Patent ductus arteriosus of the preterm infant. Pediatrics 2010, 125(5):1020–1030.
2. Clyman RI: Mechanisms regulating the ductus arteriosus. Biol Neonate 2006, 89(4):330–335.
3. Graham GG, Davies MJ, Day RO, Mohamudally A, Scott KF: The modern pharmacology of paracetamol: therapeutic actions, mechanism of action, metabolism, toxicity and recent pharmacological findings. Inflammopharmacol 2013, 21(3):201–232.
4. Van Overmere B, Smets K, Lecoutere D, Van De Broek H, Weiler J, De Grote K, Langhendries JP: A comparison of ibuprofen and indomethacin for closure of patent ductus arteriosus. N Engl J Med 2000, 343(10):674–681.
5. Ohlson A, Walia R, Shah SS: Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane database Syst Rev 2013, 30(4):CD003481.
6. Fuji AM, Brown E, Micronich M, O’Brien S, Kaufman G: Neonatal necrotizing enterocolitis with intestinal perforation in extremely premature infants receiving early indomethacin treatment for patent ductus arteriosus. J Perinatol 2002, 22(7):535–540.
7. Shorter NA, Liu JY, Mooney DP, Harmon B: Indomethacin-associated bowel perforations: a study of possible risk factors. J Pediatr Surg 1999, 34(3):442–444.
8. Bagnoli F, Rossetti A, Messina G, Mori A, Casucci M, Tornasini B: Treatment of patent ductus arteriosus (PDA) using ibuprofen: renal side-effects in VLBW and ELBW newborns. J Matern Fetal Neonatal Med 2013, 26(4):423–429.
9. Erdevci O, Sarici SU, Sari E, Gök F: Oral-ibuprofen-induced acute renal failure in a preterm infant. Pediatr Nephrol 2008, 23(8):1565–1567.
10. Akima S, Kent A, Reynolds GJ, Gallagher M, Falk MC: Indomethacin and renal impairment in neonates. Pediatr Nephrol 2004, 19(5):490–493.
11. Kanmaz G, Erdeve O, Canpolat FE, Oguç SS, Uras N, Altug N, Gejidianus B, Dilmen U: Serum ibuprofen levels of extremely preterm infants treated prophylactically with oral ibuprofen to prevent patent ductus arteriosus. Eur J Clin Pharmacol 2013, 69(9):1075–1081.
12. Hamburger C, Bin-Nun A, Markovitch E, Schimmel MS, Kaplan M, Fink D: Ductal closure with paracetamol: a surprising new approach to patent ductus arteriosus treatment. Pediatrics 2011, 128(6):e1618–e1621.
13. Oncel MY, Yurttutan S, Deggimcioglu H, Uras N, Altug N, Erdevci O, Dilmen U: Intravenous paracetamol treatment in the management of patent ductus arteriosus in extremely low birth weight infants. Neonatology 2013, 103:165–168.
14. Yurttutan S, Oncel MY, Araycio S, Uras N, Altug N, Erdeve O, Dilmen U: A different first-choice drug in the medical management of patent ductus arteriosus: oral paracetamol. J Matern Fetal Neonatal Med 2013, 26(8):825–827.

15. Oncel MY, Yurttutan S, Uras N, Altug N, Ozdemir R, Ekmen S, Erdeve O, Dilmen U: An alternative drug (paracetamol) in the management of patent ductus arteriosus in ibuprofen-resistant or contraindicated preterm infants. Arch Dis Child Fetal Neonatal Ed 2013, 98(1):F94.

16. Sinha R, Negi V, Dalal SS: An interesting observation of PDA closure with oral paracetamol in preterm neonates. J Clin Neonatol 2013, 2(1):30–32.

17. Tekgunduz KS, Ceviz N, Demirelli Y, Olgun H, Caner I, Sahin IO, Yoku C: Intravenous paracetamol for patent ductus arteriosus in premature infants - a lower dose is also effective. Neonatology 2013, 104(1):6–7.

18. Ozdemir OM, Doğan M, Kıcıktaşoğlu K, Ergin H, Sahin O: Paracetamol therapy for patent ductus arteriosus in premature infants: a chance before surgical ligation. Pediatr Cardiol 2013. [Epub ahead of print].

19. Alan S, Kahvecioglu D, Erdeve O, Atasay B, Arsan S: Is paracetamol a useful treatment for ibuprofen-resistant patent ductus arteriosus? Neonatology 2013, 104(3):168–169.

20. Roofthooft DW, van Beynum IM, Helbing WA, Reiss IK, Simons SH: Paracetamol for ductus arteriosus closure: not always a success story. Neonatology 2013, 104(3):170.

21. Dang D, Wang D, Zhang C, Zhou W, Zhou Q, Wu H: Comparison of oral paracetamol versus ibuprofen in premature infants with patent ductus arteriosus: a randomized controlled trial. PLoS One 2013, 8(11):e77888.

22. Oncel MY, Yurttutan S, Erdeve O, Uras N, Altug N, Oğuz SS, Canpolat FE, Dilmen U: Oral paracetamol versus oral ibuprofen in the management of patent ductus arteriosus in preterm infants. A randomized controlled trial. J Pediatr 2013(13):01394-2. doi: 10.1016/j.jpeds.2013.11.008. [Epub ahead of print].

23. McNamara PJ, Sehgal A: Towards rational management of the patent ductus arteriosus: the need for disease staging. Arch Dis Child Fetal Neonatal Ed 2007, 92(6):F424–F427.

24. Koch J, Hensley G, Roy L, Brown S, Ramaciotti C, Rosenfeld CR: Prevalence of spontaneous closure of the ductus arteriosus in neonates at a birth weight of 1000 grams or less. Pediatrics 2006, 117(4):1113–1121.

25. Dani C, Bertini G, Carini L, Elia S, Vangi V, Pratesi S, Rubaltelli FF: The fate of ductus arteriosus in infants at 23–27 weeks of gestation: from spontaneous closure to ibuprofen resistance. Acta Paediatr 2008, 97(9):1176–1180.

26. Chorne N, Jegatheesan P, Lin E, Shi R, Clyman R: Risk factors for persistent ductus arteriosus patency during indomethacin treatment. J Pediatr 2007, 151(6):629–634.

27. Van der Westhuizen J, Kuo PY, Reed PW, Holder K: Randomised controlled trial comparing oral and intravenous paracetamol (acetaminophen) plasma levels when given as preoperative analgesia. Anaesth Intensive Care 2011, 39(2):242–246.

28. Echtler K, Stark K, Lorenz M, Kerstan S, Walch A, Jennen L, Rudelius M, Seidl S, Kremmer E, Emambokus NR, von Bruehl ML, Frampton J, Issmann B, Genzel-Boroviczény O, Schreiber C, Mehilli J, Kastrati A, Schwaiger M, Pitz J, Anitori S, Masiberg S, Platelets contribute to postnatal occlusion of the ductus arteriosus. Nat Med 2010, 16(7):175–82.

29. Clyman R, Chembat D: Vessel remodeling in the newborn: platelets fill the gap. Nat Med 2010, 16(1):33–35.

30. Straus RS: Anaemia of prematurity: pathophysiology and treatment. Blood Rev 2010, 24(6):221–225.

31. Vandenbroucke S: Individualized developmental care for high risk newborns in the NICU: a practice guideline. Early Hum Dev 2007, 83(7):433–442.

Cite this article as: Terrin et al. Efficacy of paracetamol for the treatment of patent ductus arteriosus in preterm neonates. Italian Journal of Pediatrics 2014 40:21.